Aktienanalyse zu IQVIA Holdings Inc (IQV)IQVIQVIA Holdings Inc

IQVIA Holdings Inc. is a global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. Its segments include Commercial Solutions and Research & Development Solutions. Its commercial solutions provide mission critical information, advanced analytics, technology solutions, health care provider services (including contract sales), and patient engagement services to the Company’s life science clients. Its research & development solutions primarily serve biopharmaceutical customers, provide outsourced clinical research, clinical trial and real-world research related services. The Company offers clinical products, commercial products, compliance, safety, reg products, real world products, and others. Its clinical products include planning suite, grant plan, site suite, clinical trial payments, investigator site portal, one home for sites, patient engagement suite and others. It operates in the Healthcare sector (SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH industry).

IQVIA Holdings Inc is a good buy right now due to its current price of $259.88, which is below several analyst price targets, including $305 from BofA and $345 from UBS. The company has shown strong revenue growth, with Q2 revenues of $4.37 billion, an 8.7% year-over-year increase, and a solid forward P/E of 18.42, indicating potential for future earnings growth. However, a risk to consider is the insider selling activity, with executives reducing their holdings by 19% and 16%, which may signal caution regarding future performance.

17 analysts cover IQV: 9 rate it Buy, 8 Hold and 0 Sell. The average price target is 258.31.